3P Biopharmaceuticals, a Spanish CDMO, has inked a deal with Sweden's Intervacc to produce the company’s Strangvac equine vaccine to treat strangles.
Financial terms of the agreement weren’t disclosed.
Strangles is caused by Streptococcus equi in horses and is highly contagious. It can cause severe infection leading to significant suffering and economic loss for the global equine industry, the company said. The vaccine is the first candidate in the pipeline of a new generation of such drugs that are being developed with recombinant proteins.
“This is an important milestone in the process to complete the registration of Strangvac® and especially considering that there is a huge need for a safe and efficacious vaccine against equine strangles as evidenced by all current reported outbreaks around the world,” Jan-Ingmar Flock, Intervacc’s chief executive, said in a statement.
The agreement covers transfer of the manufacturing technology, production of validation batches and long-term future commercial manufacturing.